**PATENT** 

Attorney Docket No. 350013-71

## **CERTIFICATE OF MAILING**

I hereby certify that on May 23, 2002, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents, Box PCT, Washington, D.C. 20231.

37 CFR 1.8(a)

☑ with sufficient postage as first class mail

37 CFR 1.10

☐ as "Express Mail Post Office to Addressee" Mailing Label

.

Title: Use of Inhibitors of Mammalian Asparaginyl Endopeptidase for Therapy of Autoimmune Disease Applicant(s): Colin Watts Group Art Unit No. Unknown

Serial No. 09/646,950

Filed: December 8, 2000

Examiner: ..

Florence Thys-Doucet
(Type or print name of person mailing paper)

Http://www.

(Signature of person mailing pager)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents BOX FEE AMENDMENT Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING, COMPUTER READABLE COPY AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE (37 CFR §§ 1.821-1.825)

Dear Sir:

Responsive to the Office Action, mailed May 10, 2002, Applicant encloses herewith a copy of the SEQUENCE LISTING in computer readable (ASCII) form. A paper copy of the SEQUENCE LISTING in compliance with 37 CFR §§ 1.821-1.825 for the nucleotide and amino acid sequences disclosed in the above-referenced application is also submitted herewith.

STATEMENT THAT COMPUTER READABLE COPY OF THE SUBSTITUTE SEQUENCE LISTING IS THE SAME AS THE PAPER COPY OF THE SUBSTITUTE SEQUENCE LISTING

## I hereby state:

- 1. The computer readable (ASCII) form of the SUBSTITUTE SEQUENCE LISTING submitted in this application is the same as the paper copy of the SUBSTITUTE SEQUENCE LISTING to which it is indicated to relate.
- 2. All papers accompanying this submission introduce no new matter to the accompanying application.

## **VERIFICATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230.

Respectfully submitted,

Dated: May 23, 2002.

Buy Porter Smith, Reg. No. 20,142

Attorney for Applicant

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, Suite 3800 Los Angeles, California 90067

Telephone: (310) 788-5000 Facsimile: (310) 788-5100